PRECISION BIOSCIENCES INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
DTIL$9.50-1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)(1) Financial Statements
The following documents are included on pages F-1 through F-32 attached hereto and are filed as part of this Annual Report on Form 10-K.
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) | F-1 |
|---|---|
| Balance Sheets as of December 31, 2023 and December 31, 2022 | F-3 |
| Statements of Operations for the Years Ended December 31, 2023 and December 31, 2022 | F-5 |
| Statements of Changes in Stockholders’ Equity for the Years Ended December 31, 2023 and December 31, 2022 | F-6 |
| Statements of Cash Flows for the Years Ended December 31, 2023 and December 31, 2022 | F-7 |
| Notes to Financial Statements | F-8 |
(a)(2) Financial Statement Schedules
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.
(a)(3) Exhibits
The following is a list of exhibits filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.
Exhibit Index
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | FiledHerewith |
|---|---|---|---|---|---|---|
| 2.1†† | Asset Purchase Agreement, dated as of August 15, 2023, by and among Precision BioSciences, Inc., Imugene (USA) Inc. and Imugene Limited. | 8-K/A | 001‑38841 | 2.1 | 8/21/2023 | |
| 3.1 | Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8‑K | 001-38841 | 3.1 | 4/1/2019 | |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Precision BioSciences, Inc. | 8-K | 001-38841 | 3.1 | 2/13/2024 | |
| 3.3 | Amended and Restated Bylaws of Precision BioSciences, Inc. | 8-K | 001‑38841 | 3.1 | 12/22/2023 | |
| 4.1 | Specimen Common Stock Certificate. | S‑1/A | 333‑230034 | 4.1 | 3/18/2019 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, dated May 25, 2018, as amended, by and among Precision BioSciences, Inc. and certain of its stockholders and the holders of the 2019 Notes, | S‑1/A | 333‑230034 | 4.2 | 3/18/2019 | |
| 4.3 | Amendment No. 2, dated February 3, 2020, to the Amended and Restated Investors’ Rights Agreement, dated May 25, 2018, as amended, by and among Precision BioSciences, Inc. and certain of its stockholders and the holders of the 2019 Notes. | 8‑K | 001-38841 | 10.1 | 2/6/2020 | |
| 4.4 | Form of Indenture. | S-3 | 333-238857 | 4.3 | 6/1/2020 | |
| 4.5 | Form of Warrant. | 8-K | 001-38841 | 4.1 | 3/1/2024 | |
| 4.6 | Description of Registrant’s Securities. | * | ||||
| 10.1††† | Loan and Security Agreement, dated May 15, 2019, by and among Precision BioSciences, Inc., Elo Life Systems, Inc. and Pacific Western Bank, as amended. | 10-K | 001-38841 | 10.1 | 3/9/2023 | |
| 10.2††† | License Agreement by and among TG Therapeutics, Inc., TG Cell Therapy, Inc. and Precision BioSciences, Inc. | * | ||||
| 10.3††† | License Agreement, effective as of August 15, 2023 by and between Precision BioSciences, Inc. and Imugene (USA) Inc. | 8-K/A | 001-38841 | 10.1 | 8/21/2023 | |
| 10.4†† | Program Purchase Agreement, dated April 9, 2021, by and among Les Laboratoires Servier, Institut de Recherches Internationales Servier, and Precision BioSciences, Inc. | 10-Q | 001-38841 | 10.1 | 5/13/2021 | |
| 10.5††† | Amended and Restated Development and License Agreement, dated June 30, 2023, by and between Prevail Therapeutics, Inc. and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.1 | 7/6/2023 | |
| 10.6 | Stock Purchase Agreement, dated November 19, 2020, by and between Eli Lilly and Company and Precision BioSciences, Inc. | 10-K | 001-38841 | 10.6 | 3/18/2021 | |
| 10.7††† | Collaboration and License Agreement, dated June 14, 2022, by and between Precision BioSciences, Inc. and Novartis Pharma AG. | 8-K | 001-38841 | 10.1 | 6/21/2022 | |
| 10.8††† | Stock Purchase Agreement, dated June 14, 2022, by and between Precision BioSciences, Inc. and Novartis Pharma AG. | 8-K | 001-38841 | 10.2 | 6/21/2022 | |
| 10.9 | Registration Rights Agreement, dated June 15, 2022, by and between Precision BioSciences, Inc. and Novartis Pharma AG. | 8-K | 001-38841 | 10.3 | 6/21/2022 | |
| 10.10† | License Agreement, dated April 17, 2006, as amended, by and between Duke University and Precision BioSciences, Inc. | S‑1 | 333‑230034 | 10.2 | 3/1/2019 | |
| 10.11† | Patent Cross‑License Agreement, dated January 23, 2014, by and between Cellectis SA and Precision BioSciences, Inc. | S‑1 | 333‑230034 | 10.3 | 3/1/2019 | |
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | FiledHerewith |
|---|---|---|---|---|---|---|
| 10.12 · Lease Agreement, dated April 5, 2010, as amended, by and between Precision BioSciences, Inc. and Venable Tenant, LLC. · * | ||||||
| 10.13# | 2006 Stock Incentive Plan, as amended, and form of award agreements thereunder. | S‑1 | 333‑230034 | 10.8 | 3/1/2019 | |
| 10.14# | 2015 Stock Incentive Plan, as amended, and form of award agreements thereunder. | S‑1 | 333‑230034 | 10.9 | 3/1/2019 | |
| 10.15# | 2019 Incentive Award Plan, and forms of award agreements thereunder. | 10-K | 001-38841 | 10.14 | 3/18/2021 | |
| 10.16# | 2019 Employee Stock Purchase Plan. | S‑1/A | 333‑230034 | 10.11 | 3/18/2019 | |
| 10.17# | 2021 Employment Inducement Incentive Award Plan and form of award agreements thereunder. | S-8 | 333-259369 | 99.3 | 9/7/2021 | |
| 10.18# | Amendment to the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan. | S-8 | 333-267079 | 99.4 | 8/26/2022 | |
| 10.19# | Executive Employment Agreement, dated January 22, 2024, by and between Alex Kelly and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.2 | 1/23/24 | |
| 10.20# | Amended and Restated Executive Employment Agreement between Precision BioSciences, Inc. and Dr. Alan List, dated November 7, 2022. | 10-K | 001-38841 | 10.23 | 3/9/23 | |
| 10.21# | Executive Employment Agreement, dated January 22, 2024, by and between Dario Scimeca and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.3 | 1/23/2024 | |
| 10.22# | Executive Employment Agreement, dated January 22, 2024, by and between Jeff Smith and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.4 | 1/23/2024 | |
| 10.24# | Form of Indemnification Agreement between Precision BioSciences, Inc. and its directors and officers. | S‑1A | 333‑230034 | 10.17 | 3/18/2019 | |
| 10.25# | Non‑Employee Director Compensation Plan (as amended). | 10-Q | 001-38841 | 10.1 | 5/9/2023 | |
| 10.26# | Executive Employment Agreement, dated January 22, 2024, by and between Michael Amoroso and Precision BioSciences, Inc. | 8-K | 001-38841 | 10.1 | 1/23/2024 | |
| 21.1 | Subsidiaries of Precision BioSciences, Inc. | * | ||||
| 23.1 | Consent of Deloitte & Touche LLP. | * | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | * | ||||
| 32.1 | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 32.2 | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ** | ||||
| 97 | Clawback policy | |||||
| 101.INS | XBRL Instance Document | * | ||||
| ExhibitNumber | Description | Form | File No. | Exhibit | FilingDate | FiledHerewith |
| 101.SCH | XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (as formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith
** Furnished herewith
†Confidential treatment of certain provisions has been granted by the SEC pursuant to Rule 406 under the Securities Act of 1933, as amended.
††Portions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K.
†††Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
#Denotes a management contract or compensatory plan or arrangement
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.